Cefotaxime Treatment of Pelvic Inflammatory Disease
Open Access
- 1 December 1981
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 20 (6) , 847-849
- https://doi.org/10.1128/aac.20.6.847
Abstract
We studied cefotaxime in the treatment of gonococcal and nongonococcal pelvic inflammatory disease. Cefotaxime was uniformly effective against gonococcal pelvic inflammatory disease. However, 4 of 11 patients with nongonococcal pelvic inflammatory disease had a suboptimal response.This publication has 11 references indexed in Scilit:
- In Vitro Activity of HR 756, a New Cephalosporin, Against Neisseria gonorrhoeaeAntimicrobial Agents and Chemotherapy, 1979
- HR 756, a Highly Active Cephalosporin: Comparison with Cefazolin and CarbenicillinAntimicrobial Agents and Chemotherapy, 1978
- Cefotaxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitroJournal of Antimicrobial Chemotherapy, 1978
- Antimicrobial Activity of Several Antibiotics and a Sulfonamide Against Chlamydia trachomatis Organisms in Cell CultureAntimicrobial Agents and Chemotherapy, 1977
- Chlamydia trachomatisInfection in Patients with Acute SalpingitisNew England Journal of Medicine, 1977
- Comparison of API and Minitek to Center for Disease Control methods for the biochemical characterization of anaerobesJournal of Clinical Microbiology, 1976
- Polymicrobial Etiology of Acute Pelvic Inflammatory DiseaseNew England Journal of Medicine, 1975
- Anaerobic Infections: Old Myths and New RealitiesThe Journal of Infectious Diseases, 1974